Results 11 to 20 of about 76,081,297 (156)

Non-spatial and spatial heterogeneity revealed a suppressive immune feature of Siglec-15 in lung adenocarcinomas [PDF]

open access: yesJournal of Translational Medicine, 2023
Background Sialic acid-binding immunoglobulin-like lectin-15 (Siglec-15) has emerged as a novel immunotherapy candidate, which deserves a comprehensive investigation in lung adenocarcinoma (LUAD). Methods Multiplex fluorescence‐based immunohistochemistry
Baihui Li   +6 more
doaj   +3 more sources

Analysis of a Novel Immune Checkpoint, Siglec-15, in Pancreatic Ductal Adenocarcinoma [PDF]

open access: yesJournal of Pathology: Clinical Research, 2022
Siglec‐15, a novel immune checkpoint, is an emerging target for next‐generation cancer immunotherapy. However, the role of Siglec‐15 in pancreatic ductal adenocarcinoma (PDAC) remains poorly understood. We investigated the expression of Siglec‐15 and its
Jie Chen, Shuangni Yu, Yue Zhang
exaly   +3 more sources

Significance of Siglec-15 Expression in Colorectal Cancer: Association With Advanced Disease Stage and Fewer Tumor-Infiltrating Lymphocytes [PDF]

open access: yesJournal of Pathology: Clinical Research, 2023
Siglec‐15, a novel immune suppressor, is upregulated in many human cancers. The aim of this study was to explore the expression of Siglec‐15 in colorectal cancer (CRC), and investigate whether Siglec‐15 could be a potential target for cancer ...
Bingzhi Wang, Pu Cheng, Zhao Lu
exaly   +3 more sources

The expression characteristic and prognostic role of Siglec‐15 in lung adenocarcinoma [PDF]

open access: yesThe Clinical Respiratory Journal
Sialic acid‐binding immunoglobulin‐like lectin‐15 (Siglec‐15) has been identified as an immune suppressor and a promising candidate for immunotherapy of cancer management.
Haijun Sun   +7 more
doaj   +3 more sources

Siglec–15 promotes a feed-forward loop between TNBC cells and macrophages via the NF-κB/DcR3/CCL18/STAT3 axis [PDF]

open access: yesTranslational Oncology
M2-like tumor-associated macrophages (TAMs), recognized as a significant risk factor in tumor progression, play a crucial role in the tumor microenvironment. While Sialic acid binding Ig like Lectin 15 (Siglec-15), an well-characterized immune-checkpoint
Sizhang Wang   +5 more
doaj   +3 more sources

Siglec-15 as a New Perspective Therapy Target in Human Giant Cell Tumor of Bone [PDF]

open access: yesCurrent Oncology, 2022
The main features of a giant cell tumor of bone (GCTB) are frequent recurrence and aggressive osteolysis, which leads to a poor prognosis in patients.
Mengke Fan   +5 more
doaj   +3 more sources

Siglec-15 antibody–GM-CSF chimera suppresses tumor progression via reprogramming tumor-associated macrophages [PDF]

open access: yesJournal for ImmunoTherapy of Cancer
Background Sialic acid-binding immunoglobulin-like lectin (Siglec)-15-expressing tumor-associated macrophages (TAMs) drive immunosuppression in the tumor microenvironment (TME), promoting CD8+ T cell exhaustion and limiting immunotherapy efficacy.
Jun Li   +12 more
doaj   +3 more sources

Identification of BACH1-IT2-miR-4786-Siglec-15 immune suppressive axis in bladder cancer [PDF]

open access: yesBMC Cancer
The sialic acid binding Ig like lectin 15 (Siglec-15) was previously identified as tumor immune suppressor gene in some human cancers with elusive molecular mechanism to be elucidated.
Xingzhi Li   +6 more
doaj   +3 more sources

Siglec-15 as a potential molecule involved in osteoclast differentiation and bone metabolism [PDF]

open access: yesHeliyon
Sialic acid-binding immunoglobulin-like lectin 15 (Siglec-15) is a well-conserved type I transmembrane protein of the Siglecs family, distributed in macrophages and dendritic cells in the human spleen and lymph nodes.
Jiaqi Lu   +5 more
doaj   +3 more sources

Stromal immune cells expression of Siglec-15 is associated with lower T stage and better prognosis of urinary bladder cancer [PDF]

open access: yesFrontiers in Oncology
IntroductionSialic acid-binding immunoglobulin-like lectin 15 (Siglec-15) is a novel immune checkpoint, similar to programmed death-ligand (PD-L1), and has emerged as a potential target for cancer immunotherapy. Until recently, little was known about the
Chengbiao Chu   +4 more
doaj   +4 more sources

Home - About - Disclaimer - Privacy